SYSTEMATIC REVIEW article
Front. Gastroenterol.
Sec. Therapy in Gastroenterology
Role of Thalidomide in Angiodysplasia-related Gastrointestinal bleeding: A Systematic Review
Provisionally accepted
Junaid Khan1*
Amna Yousaf Shah2Aamir Asif Khan3Zubair Ahmed Mbbs4
Mahad Shahid Raja5
Ruqaiya Shahid Raja6Simona Eng Do7Qamar Iqbal7- 1Peninsula Regional Medical Center, Salisbury, United States
- 2University at Buffalo, Buffalo, United States
- 3University Hospital Kerry, Tralee, Ireland
- 4Fatima Memorial Hospital, Lahore, Pakistan
- 5Akhtar Saeed Medical and Dental College, Lahore, Pakistan
- 6Shifa College of Medicine, Islamabad, Pakistan
- 7TidalHealth Peninsula Regional, Salisbury, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: Angiodysplasia of the gastrointestinal (GI) tract is a leading cause of occult GI bleeding, and its management remains challenging. Various pharmacologic and endoscopic therapies are used with limited success. This systematic review evaluates the clinical efficacy of thalidomide in angiodysplasia-related GI bleeding. Methods: A comprehensive literature search was conducted across PubMed, Embase, Scopus, and CINAHL using MeSH terms "Vascular malformations" OR "Angiodysplasia" AND "Thalidomide," covering the period from 1994 to February 16, 2024. We included clinical trials and case series with at least five adult patients treated with thalidomide for angiodysplasia-related GI bleeding. Six studies met the inclusion criteria: two randomized controlled trials (RCTs), one retrospective observational study, and three case series (Figure 1). Results: A total of 265 patients were included, with a median age of 63.5 years; 37% were male. Angiodysplasia was diagnosed using endoscopy, colonoscopy, or push enteroscopy. Clinical outcomes varied across studies. Garrido et al. reported an 84% response rate based on hemoglobin improvement. In an RCT, Chen et al. demonstrated reduced bleeding episodes in 68.6% of patients receiving thalidomide 100 mg compared with 51% in the 50 mg group. Ge et al. reported a response rate of 71.4% (20/28) in the thalidomide group versus 3.7% (1/27) in the iron group (risk difference 67.7%, 95% CI 51.1–84.2). Common adverse effects included constipation, dizziness, fatigue, limb numbness, and peripheral neuropathy. Conclusion: Thalidomide appears effective in reducing bleeding episodes in angiodysplasia-related GI bleeding. However, heterogeneity in dosing, outcome definitions, and safety reporting highlights the need for larger, standardized trials to clarify optimal treatment strategies and long-term safety.
Keywords: Angiodysplasia, atriovenous malformation, Gastrointestinal bleed, GIB, Thalidomide
Received: 20 Jul 2025; Accepted: 12 Feb 2026.
Copyright: © 2026 Khan, Yousaf Shah, Khan, Mbbs, Shahid Raja, Shahid Raja, Do and Iqbal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Junaid Khan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.